On October 6, Tempus AI fell 7.04% in regular trading, trading at $77.74/share with turnover of $255 million.
The decline was driven by ongoing large-scale insider selling, which overshadowed recent positive regulatory and partnership developments. CEO and Chairman Eric Lefkofsky has sold more than 1 million Class A common shares since mid-September at prices between $76 and $81, according to recent filings. The concentrated divestment, combined with bearish option market signals, exerted clear pressure on the stock.
Although Tempus AI recently received FDA 510(k) clearance for its ECG-MR product and extended its data license agreement with Recursion, the negative signal from executive selling dominated trading on the day.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)